Heart failure is classified into four types based on left ventricular ejection fraction (LVEF) and clinical presentation: heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), heart failure with mildly reduced ejection fraction (HFmrEF), and acute decompensated heart failure (ADHF). These categories define how well the heart pumps blood and guide treatment decisions.
Doctors measure ejection fraction using echocardiography, which calculates the percentage of blood pumped out of the left ventricle with each heartbeat. A normal LVEF is 50% or higher. When the heart's pumping ability declines below this threshold, it signals systolic dysfunction.
HFrEF occurs when LVEF is 40% or lower. This indicates the heart muscle is weak and cannot contract effectively. Patients often report shortness of breath during exertion, fatigue, and swelling in the legs. The condition results from damage to the myocardium due to prior heart attacks, cardiomyopathy, or long-term hypertension.
HFpEF happens when LVEF remains at or above 50%, meaning the heart contracts normally but fails to relax properly during diastole-the filling phase. This leads to increased pressure in the heart chambers and fluid backup into the lungs. It is common in older adults, especially those with diabetes, obesity, or chronic kidney disease.
The American Heart Association and European Society of Cardiology recognize three primary subtypes based on ejection fraction:
| Type | LVEF Range | Key Mechanism | Common Triggers |
|---|---|---|---|
| HFrEF | <40% | Systolic dysfunction - weak contraction | Myocardial infarction, dilated cardiomyopathy |
| HFmrEF | 41%-49% | Mildly impaired contraction | Intermediate stage between HFrEF and HFpEF |
| HFpEF | ≥50% | Diastolic dysfunction - stiff ventricle, poor filling | Hypertension, metabolic syndrome, aging |
ADHF is not a subtype by ejection fraction but a clinical state. It describes sudden worsening of symptoms-such as severe dyspnea, orthopnea, or pulmonary edema-requiring urgent medical intervention. ADHF can occur in any type of heart failure but is most frequently seen in HFrEF patients.
Treatment strategies differ between HFrEF and HFpEF. For HFrEF, guideline-directed medical therapy (GDMT) includes beta-blockers like carvedilol, ACE inhibitors such as lisinopril, and mineralocorticoid receptor antagonists like spironolactone. These drugs improve survival and reduce hospitalizations.
For HFpEF, no medication has consistently shown mortality benefit in large trials. Management focuses on controlling comorbidities: treating hypertension, managing diabetes, reducing weight, and addressing sleep apnea. SGLT2 inhibitors (like dapagliflozin) have recently shown promise in reducing heart failure events in HFpEF patients, though they do not extend life expectancy.
A key misconception is that HFpEF is less serious than HFrEF. It is not. HFpEF accounts for about half of all heart failure cases and carries a similar risk of hospitalization and death. The difference lies in recognition-many clinicians still underestimate its prevalence and severity.
A 68-year-old woman presents with progressive shortness of breath on walking two blocks. She has a history of type 2 diabetes, hypertension, and obesity. Her echocardiogram shows an LVEF of 55% and evidence of elevated left atrial pressure. Left ventricular wall thickness is increased, consistent with hypertrophy.
Despite normal ejection fraction, she meets criteria for HFpEF. Her symptoms and imaging findings indicate impaired relaxation and increased stiffness. She is started on antihypertensives, metformin optimization, and dapagliflozin. Over six months, her exercise tolerance improves, and she reports fewer episodes of breathlessness.
This case illustrates that heart failure is not solely about pumping strength-it involves filling capacity too. Misdiagnosis is common when clinicians rely only on ejection fraction.
Many assume heart failure always involves low pumping power. That's incorrect. Nearly 50% of heart failure cases are HFpEF, where the heart contracts normally but fills poorly. This misunderstanding delays diagnosis and treatment.
Another error is equating heart failure with a heart attack. They are distinct conditions. A heart attack damages heart tissue, potentially leading to HFrEF. But heart failure can develop gradually over years without prior cardiac injury.
Some patients believe they feel pain during heart failure episodes. While chest discomfort can occur, it is not typical. Pain in heart failure is usually absent or mild. When present, it may stem from other causes like angina or musculoskeletal strain. Pain in heart failure is not a defining feature.
In my time working in cardiology clinics, I've seen patients mislabel their symptoms as "heart failure" because they feel tired or short of breath. One man with COPD was diagnosed with HFpEF after a routine echo showed preserved EF. His symptoms improved only after we addressed his undiagnosed sleep apnea and optimized his blood pressure control. This case underscores that symptom overlap requires careful evaluation.
Recognizing that heart failure is not one disease but a spectrum of disorders helps avoid misdiagnosis and ensures timely intervention. The correct classification determines whether therapy targets contractility, filling, or both.